Ronald Witteles
YOU?
Author Swipe
View article: Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy
Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy Open
Background Most patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) are diagnosed noninvasively, using nuclear imaging and monoclonal protein testing. However, concerns have been raised that some may receive an ATTRwt-…
View article: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM Open
Acoramidis significantly reduced the cumulative burden of CV outcomes in ATTR-CM over 30 months. Numerically fewer events were observed with acoramidis vs placebo by month 1, and the difference increased progressively over time, resulting …
View article: Vutrisiran in Transthyretin Amyloidosis
Vutrisiran in Transthyretin Amyloidosis Open
View article: Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy Open
cTnI surveillance integrated with symptom-based triaging can facilitate early intervention and treatment of cardiotoxicities such as myocarditis.
View article: Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis Open
In patients with ATTR-CM treated with patisiran, mean population-level differences of 7 to 8 m in 6MWT have practical relevance. The magnitude of the impact of patisiran on 6MWT performance over 12 months in APOLLO-B was associated with pr…
View article: Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis Open
View article: Global Practices in Cardiac Imaging for Cardiac Sarcoidosis
Global Practices in Cardiac Imaging for Cardiac Sarcoidosis Open
Several consensus areas for cardiac imaging in suspected and established cardiac sarcoidosis were identified. This consensus study identified areas of priority for future prospective, controlled, multicenter research studies.
View article: Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary Open
What is this summary about?
View article: Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy Open
Consistent with the primary trial results, vutrisiran reliably reduced the risk of ACM, CV mortality, CV hospitalizations, HF hospitalizations, and urgent HF visits vs placebo in patients with ATTR-CM. (HELIOS-B: A Study to Evaluate Vutris…
View article: Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review Open
Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This nar…
View article: Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up Open
View article: Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis Open
The demographics of patients with transthyretin amyloidosis with cardiomyopathy have evolved over the past decade, mostly driven by improved awareness of the disease among clinicians, noninvasive imaging tools for diagnosis, and new, effec…
View article: Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Open
BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therap…
View article: Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy Open
Importance Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic valu…
View article: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Open
Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B C…
View article: Drug Development for Transthyretin Amyloidosis
Drug Development for Transthyretin Amyloidosis Open
View article: Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis
Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis Open
View article: Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy
Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy Open
View article: Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT Open
Renal function deteriorates over time in patients with ATTR-CM, and tafamidis treatment was associated with a reduction in this deterioration, and a higher incidence of improved eGFR and CKD staging over 30 months compared with placebo. (S…
View article: A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis
A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis Open
Background Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate of up to 40%, with severe cardiovascular consequences. Ta…
View article: THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY Open
Purpose Immune checkpoint inhibitors (ICI) used as cancer therapy have been associated with a range of cardiac immune-related adverse events (irAEs), including fulminant myocarditis with a high case fatality rate. Early detection through c…
View article: Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research Open
Purpose of the Review Even as immune checkpoint inhibitors (ICIs) have transformed the lifespan of many patients, they may also trigger acceleration of long-term cardiovascular disease. Our review aims to examine the current landscape of r…
View article: Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation
Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation Open
Hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN) results from specific TTR gene mutations. In this study, we generated two induced pluripotent stem cell (iPSC) lines derived from ATTR-PN patients with heterozygous TTR gen…
View article: Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study Open
The findings demonstrate tafamidis efficacy for patients with ATTR-CM both in those aged <80 and those aged ≥80 years. (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]; NCT01994889/Long-term Safety of Tafamidis in Subje…
View article: A fast, novel technique for detection of left ventricular hypertrophy by electrocardiography
A fast, novel technique for detection of left ventricular hypertrophy by electrocardiography Open
Background Electrocardiography (ECG) is a widely used non-invasive tool for detecting left ventricular hypertrophy (LVH), but existing techniques suffer from complex rules and limited sensitivity. Purpose The goal of this study was to desi…
View article: Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer
Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer Open
View article: Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation
Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation Open
View article: Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis Open
Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new…
View article: Development and validation of a rapid visual technique for left ventricular hypertrophy detection from the electrocardiogram
Development and validation of a rapid visual technique for left ventricular hypertrophy detection from the electrocardiogram Open
Introduction Left ventricular hypertrophy (LVH) detection techniques on by electrocardiogram (ECG) are cumbersome to remember with modest performance. This study validated a rapid technique for LVH detection and measured its performance ag…
View article: Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay Open
No abstract available